Steven Theriault | Chief Executive Officer & Chief Science Officer
Cytophage Technologies

Steven Theriault, Chief Executive Officer & Chief Science Officer, Cytophage Technologies

Dr. Steven Theriault is a versatile scientist, researcher, educator, and entrepreneur who began his career as a paramedic before turning his attention to biomedical research.  he obtained his PhD from the University of Manitoba (U of M) including studies in microbiology, genetics virology, and molecular biology.  During his doctoral studies, he made significant contributions to the study of the Zaire Ebola Virus, leading to the development of the Canadian Ebola vaccine.  Since 2006, Dr. Theriault has been an Associate Professor in the Departments of Microbiology and Medical Microbiology at U of M, where he serves as a lecturer in Applied Biosafety Research for both graduate and undergraduate programs. Dr. Theriault's career continued to evolve as he joined the Public Health Agency of Canada's National Microbiology Laboratory, where he addressed antimicrobial resistance (AMR) issues through biosafety, laboratory security, and environmental protection research.  His expertise and dedication extended globally, as he worked on issues related to AMR, microbicide efficacy, pathogenesis evaluation in viral infectious agents, and advancements in decontamination. He is currently the CEO and CSO of Cytophage Technologies, a biotech company he found to combat AMR by developing highly effective bacteriophages using advanced molecular genetic techniques.  These bacteriophages combat bacterial infection and contamination affecting human health, animal health and food security.  Cytophage was recently featured in Life Sciences Review magazine as one of the top 10 therapeutics companies in Canada. Dr. Theriault has been an invited speaker/presenter at numbers global conferences and served on various boards.  He is currently serving as a member of the Expert Committee for the Canada Foundation for Innovation, Canada's Biomedical Research Fund, and Biosciences Research Infrastructure Fund.    

Appearances:



Pre-Congress Workshops - Monday 1st April @ 10:00

ANTIMICROBIAL RESISTANCE - Role of vaccines, mABs, phages and antibiotics [F2]

A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens? 

10:00 Chair opening remarks

10:10 Accelerating the Development of Novel Tools against AMR Dr Richard Alm, Chief Scientist, CARB-X

10:40 The application of phages to treat bacterial infectionsDr Steven Theriault, CEO & CSO, Cytophage

10:10

11:40 The Significance of Robust Health and Economic Data in Tackling Antimicrobial ResistanceLatifat Okara, Principal, Health Policy and Insights, The Economist Impact  

12:00-1:00 Panel: What is our AMR strategy: ESKAPE and Priority Pathogens?

  • Which pathogens are more appropriate for vaccine vs mABs development?
  • Challenges of ESKAPE pathogens and innovative approaches.
  • Pre-emptive therapies for patients with colonization of pathogens

Dr Tim Cooke, CEO, Omniose Dr Bret Sellman, Executive Director, Vaccine and Immune Therapies and Head of Bacteriology and Vaccines Discovery, Astrazeneca Dr Francesca Micoli, Director GVGH Innovation Academy and Senior Project Leader, GSK Vaccine Institute for Global Health Dr Kimberly Taylor, Senior Scientific Officer, Concept Acceleration Program, NIAID

1:00 - 2:00 Lunch Break 

2:00 Combination Vaccines Dr William Hausdorff, Public Health Value Proposition Lead, PATH

2:30 Shigella and ETEC vaccines Dr Chad Porter, Department Head Translational and Clinical Research Defense Infectious Diseases Directorate, Naval Medical Research Center

3:00 Serotype Independent Pneumococcal Vaccine Dr Tim Hirst, CEO, GPN Vaccines

3:30 Developing Pseudomonas and Klebsiella vaccines using a reverse vaccinology approachDr Rebecca Ingram, Senior Lecturer, Queens University Belfast

3:45 Update on C. diff vaccine development Dr Erik Lamberth, Senior Director, Vaccine Clinical Research and Development, Pfizer

4:00-5:00 Panel: Defining the value of vaccines against AMR

  • Measuring the economic and social value of vaccines as a tool against AMR
  • The importance of a One Health approach
  • Understanding the role and impact of vaccines for AMR in LMIC
  • Combatting vaccine hesitancy and misinformation for the uptake of vaccines to prevent AMR.

Moderator: Dr Jomana Musmar, Executive Director, PACCARBDr Jessica Pickett, Director, US Vaccines Health Economics and Outcomes Research, GSK Dr Fadi Makki, Partner and Director, BCG Dr John Jernigan, Chief, Epidemiology Research and Innovations Branch Division of Healthcare Quality Promotion, CDC

last published: 26/Feb/24 13:16 GMT

back to speakers